Specialty Pharmacy

Ambitious project marks new era for pancreatic cancer patients, investigators say.

Top news of the day from across the health care landscape.

Sirukumab is a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity in RA.

Defendants charged with conspiracy to commit health care fraud and money laundering.

Suzette DiMascio, CHE, CMCE, CPC, president and CEO of CSI Specialty Group, discusses how to optimize a drug adherence program in specialty pharmacy.

Top news of the week in oncology and cancer drug development.

Health care reform discussed at Premier Inc’s 6th Annual Specialty Pharmacy Executive Retreat.

Overexpression of protein reveals why breast cancer spreads quickly.

Genetic testing and imaging tests will improve neuroendocrine treatment.

Scientists identify specific genes that cooperate with a well-known tumor suppressor gene.

The smartphone hit the shelves recently.

Study identifies 2 immune system molecules that may play a key role in drug-resistance.

The rheumatoid arthritis (RA) drug market is projected to reach approximately $28.5 billion by 2025.

More biosimilar approvals may lead to lower costs.

Study identifies potential Achilles heel of kinase-driven cancers.

Majority of patients were free from local recurrence after 1 year of reirradiation with an advanced form of proton therapy.

Top news of the day from across the health care landscape.

Ocrelizumab (Ocrevus) granted FDA approval to treat 2 forms of MS.

Novel test demonstrates the benefits of exercise in individuals with neurological injuries and illnesses.

New tuberculosis cases have declined over the past 5 years, but new data show rates are up for TB/HIV coinfections.

Eric Peacock, co-founder and CEO of MyHealthTeams, discusses the importance of specialty pharmacies collaborating with patients in their care.

Neurologist Michael Racke, MD, discusses the new FDA approval of ocrelizumab and how it will impact the future treatment of MS.

Injection helps clear skin and manage itch severity caused by the disease.

More than 3000 patients with breast cancer have received radiation with the Xoft System.

Treatment with endostatin slowed the proliferation of resistant prostate cancer cells.

Eculizumab (Soliris) can reduce disease burden for patients with refractory generalized myasthenia gravis.

Top news of the day from across the health care landscape.

Epalrestat could prevent metastasis in patients with basal-like triple-negative breast cancer.